陸國(guó)玉吳曉飛張曉華周 蕾
(蚌埠醫(yī)學(xué)院第一附屬醫(yī)院1急診科,2臨床病理科,蚌埠 233003)
?
胃腺癌中Twist、Snail與KAI1的免疫反應(yīng)性及其臨床意義
陸國(guó)玉1吳曉飛1張曉華1周 蕾2*
(蚌埠醫(yī)學(xué)院第一附屬醫(yī)院1急診科,2臨床病理科,蚌埠 233003)
目的 檢測(cè)原發(fā)性胃腺癌(gastric adenocarcinoma,GAC)中上皮間充質(zhì)轉(zhuǎn)化(epithelial mesenchymal transition,EMT)相關(guān)標(biāo)記物Twist和Snail蛋白以及腫瘤轉(zhuǎn)移抑制因子KAI1水平,并分析它們之間的相互關(guān)系以及臨床意義。方法通過(guò)免疫組織化學(xué)ElivisionTMplus法檢測(cè)261例GAC和80例正常胃黏膜組織中Twist、Snail和KAI1蛋白的免疫反應(yīng)性。結(jié)果 Twist和Snail在GAC組織中的免疫反應(yīng)陽(yáng)性率顯著高于其在對(duì)照組中的陽(yáng)性率;KAI1蛋白在GAC組織中的免疫反應(yīng)陽(yáng)性率顯著低于其在對(duì)照組中免疫反應(yīng)陽(yáng)性率。Twist和Snail蛋白免疫反應(yīng)陽(yáng)性率與GAC組織的浸潤(rùn)深度、臨床病理分期和淋巴結(jié)轉(zhuǎn)移均顯著相關(guān);KAI1蛋白的免疫反應(yīng)陽(yáng)性率與GAC腫瘤組織的分化程度、浸潤(rùn)深度、臨床病理分期及淋巴結(jié)轉(zhuǎn)移顯著相關(guān)。Kaplan-Meier生存分析顯示,Twist和Snail蛋白免疫反應(yīng)陽(yáng)性組患者的總體生存時(shí)間明顯短于其陰性組患者,而KAI1蛋白免疫反應(yīng)陽(yáng)性組的患者總體生存時(shí)間明顯長(zhǎng)于其陰性組患者。Spearman相關(guān)分析顯示,KAI1蛋白與Twist和Snail蛋白的免疫反應(yīng)性之間呈負(fù)相關(guān),Twist和Snail的免疫反應(yīng)性呈正相關(guān)。COX多因素回歸分析表明Twist和KAI1蛋白的免疫反應(yīng)陽(yáng)性以及pTNM分期是影響GAC患者生存的獨(dú)立預(yù)后因素。結(jié)論 Twist、Snail水平升高和KAI1水平降低可能參與了GAC的浸潤(rùn)及轉(zhuǎn)移過(guò)程;聯(lián)合檢測(cè)Twist、Snail和KAI1的免疫反應(yīng)性對(duì)GAC患者的腫瘤進(jìn)展及預(yù)后判斷有重要意義。
胃腫瘤;Twist;Snail;KAI1;預(yù)后
胃癌的發(fā)病率在惡性腫瘤中位于第五位,中國(guó)是胃癌高發(fā)國(guó)家,占全球新發(fā)病例的40%[1-2]。大多數(shù)胃癌患者的術(shù)后治療效果不佳,轉(zhuǎn)移和復(fù)發(fā)是其主要原因。上皮間充質(zhì)轉(zhuǎn)化(epithelial mesenchymal transition,EMT)與轉(zhuǎn)移過(guò)程非常相似。所謂EMT過(guò)程是指上皮細(xì)胞在一些特定的生理或病理情況下向間充質(zhì)細(xì)胞轉(zhuǎn)化,上皮細(xì)胞的極性和黏附性降低或喪失、細(xì)胞骨架重組,同時(shí)伴有上皮細(xì)胞相關(guān)表型(例如CK、E-cadherin等)喪失,而間充質(zhì)相關(guān)表型(例如vimentin、Twist、Snail等)表達(dá)增多[3]。這些均導(dǎo)致腫瘤細(xì)胞的運(yùn)動(dòng)能力增強(qiáng)而易于脫離母體造成侵襲和轉(zhuǎn)移。Twist是EMT的關(guān)鍵標(biāo)記物,是具有bHLH(basic helix-loop-helix,bHLH)結(jié)構(gòu)的轉(zhuǎn)錄因子[4],其在腫瘤組織中表達(dá)增高往往意味著腫瘤細(xì)胞易于侵襲、轉(zhuǎn)移及預(yù)后不良[5-7]。轉(zhuǎn)錄因子Snail是EMT過(guò)程中另一個(gè)關(guān)鍵因子,是具有鋅指結(jié)構(gòu)的超家族中的關(guān)鍵成員,其家族成員包括Snail(Snail1)、Slug(Snail2)和Smug(Snail3)[8]。Snail可以通過(guò)抑制CDH1的轉(zhuǎn)錄而導(dǎo)致E-cadherin的表達(dá)降低或缺失,從而促進(jìn)EMT的形成[9]。Snail表達(dá)增高與腫瘤侵襲和復(fù)發(fā)有關(guān)[10]。KAI1是一種腫瘤轉(zhuǎn)移抑制因子,其表達(dá)降低或缺失促進(jìn)腫瘤的侵襲及轉(zhuǎn)移。KAI1最早是在前列腺癌中被發(fā)現(xiàn)的,是前列腺癌特異性的轉(zhuǎn)移抑制基因。近20年來(lái)在其它多種腫瘤中發(fā)現(xiàn)KAI1的表達(dá)是降低或缺失的,而其表達(dá)降低或缺失往往與腫瘤的浸潤(rùn)、轉(zhuǎn)移及預(yù)后[11-13]相關(guān)。盡管TNM分期作為原發(fā)性胃腺癌(gastric adenocarcinoma,GAC)患者治療依據(jù)已得到廣泛的認(rèn)可,但TNM分期不能反映每一個(gè)GAC組織的生物學(xué)行為,因此迫切需要尋找到能夠反映GAC生物學(xué)行為、且能夠?qū)NM分期作出有益補(bǔ)充的生物學(xué)標(biāo)記。本研究通過(guò)免疫組織化學(xué)ElivisionTMplus法研究檢測(cè)261例GAC患者腫瘤組織中Twist、Snail和KAI1蛋白的免疫反應(yīng)性,分析它們之間的關(guān)系,旨在尋找能夠預(yù)測(cè)GAC患者浸潤(rùn)、轉(zhuǎn)移及預(yù)后的新指標(biāo)。
1 一般資料
收集蚌埠醫(yī)學(xué)院第一附屬醫(yī)院臨床病理科2004年1月~2005年12月存檔石蠟包埋GAC組織(術(shù)前均未行放、化療及生物治療等抗腫瘤治療)261例和正常胃黏膜組織80例作回顧性研究,所有病例都有完整的臨床病理及隨訪(fǎng)資料。入選病例隨訪(fǎng)至患者死亡或截止至2013年4月,隨訪(fǎng)時(shí)間為8~110月。所有GAC診斷均在本院病理科證實(shí)。臨床病理資料包括GAC患者年齡、性別、腫瘤大小、腫瘤位置、腫瘤類(lèi)型、浸潤(rùn)深度、分化程度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期等。
80例對(duì)照組正常胃黏膜組織均取自遠(yuǎn)離GAC腫塊5.0cm,且經(jīng)病理科H&E染色證實(shí)為正常胃黏膜組織。
2 試劑
兔抗人Twist多克隆抗體及鼠抗人Snail單克隆抗體均購(gòu)自美國(guó)Abcam公司;鼠抗人KAI1單克隆抗體購(gòu)自美國(guó)Santa Cruz公司;ElivisionTMplus及DAB顯色試劑盒購(gòu)自福州邁新生物技術(shù)開(kāi)發(fā)有限公司。
3 免疫組織化學(xué)染色
所有標(biāo)本均經(jīng)10%中性甲醛溶液固定,石蠟包埋,以4μm厚連續(xù)切片、烤干,最后通過(guò)二甲苯和濃度梯度乙醇溶液脫蠟至水洗。免疫組織化學(xué)操作均根據(jù)試劑盒說(shuō)明書(shū)進(jìn)行。采用已知陽(yáng)性片作對(duì)照,以相應(yīng)動(dòng)物的IgG替代一抗作陰性對(duì)照。
4 結(jié)果判定與統(tǒng)計(jì)分析
Twist是以細(xì)胞質(zhì)出現(xiàn)黃色或棕黃色顆粒為陽(yáng)性,也會(huì)出現(xiàn)胞核著色;Snail是以細(xì)胞核出現(xiàn)黃色或棕黃色顆粒為陽(yáng)性;KAI1是以細(xì)胞膜和漿出現(xiàn)黃色或棕黃色顆粒為陽(yáng)性。采取二次計(jì)分法,每例標(biāo)本隨機(jī)計(jì)數(shù)10個(gè)高倍視野(×400),計(jì)數(shù)每個(gè)高倍視野中陽(yáng)性細(xì)胞所占百分比并計(jì)分;分析染色強(qiáng)度并計(jì)分。具體步驟見(jiàn)參考文獻(xiàn)[14]。最后將陽(yáng)性細(xì)胞數(shù)得分和染色強(qiáng)度得分的乘積作為表達(dá)判斷結(jié)果,若積分≥3分為陽(yáng)性,<3分為陰性。免疫組化標(biāo)記結(jié)果由兩位病理醫(yī)師通過(guò)獨(dú)立雙盲法判定。
采用SPSS20.0統(tǒng)計(jì)軟件包進(jìn)行統(tǒng)計(jì)分析。Twist、Snail和KAI1蛋白免疫反應(yīng)陽(yáng)性組與陰性組的生存分析采用Kaplan-Meier法,組間比較用logrank檢驗(yàn);多因素分析采用COX多因素回歸模型進(jìn)行分析。在GAC腫瘤組織中,Twist、Snail和KAI1蛋白的免疫反應(yīng)性與正常胃黏膜組織、各臨床病理參數(shù)的相關(guān)性采用Χ2、Spearman等級(jí)相關(guān)檢驗(yàn),P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
1 Twist免疫反應(yīng)性增高促進(jìn)GAC的浸潤(rùn)和轉(zhuǎn)移
Twist蛋白在對(duì)照組中的免疫反應(yīng)陽(yáng)性率為2.5%,在GAC組中的免疫反應(yīng)陽(yáng)性率為62.1%(圖1A,圖1B),GAC組較對(duì)照組顯著升高。Twist蛋白的陽(yáng)性率與GAC腫瘤組織的浸潤(rùn)深度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期均有關(guān)。Twist蛋白的陽(yáng)性率與GAC患者的性別、腫瘤大小、腫瘤位置、腫瘤類(lèi)型及分化程度等無(wú)關(guān)(表1)。
圖1 Twist、Snail和KAI1在GAC和對(duì)照組中的免疫組織化學(xué)染色。A,Twist在GAC組織中的陽(yáng)性染色,主要定位于細(xì)胞漿(中分化);B,Twist在對(duì)照組中的陰性染色;C,Snail在GAC組織中的陽(yáng)性染色,主要定位于細(xì)胞核(低分化);D,Snail在對(duì)照組中的陰性染色;E,KAI1在GAC中的陰性染色(中分化);F,KAI1在對(duì)照組中的陽(yáng)性染色,主要定位于細(xì)胞膜和細(xì)胞漿。比例尺=100μmFig.1 Immunostaining of Twist、Snail、KAI1 in the GAC and control tissues.A,Positive immunoreactivity of Twist in the cytoplasm of GAC(moderate differentiation);B,Negative immunoreactivity of Twist in the control group;C,Positive immunoreactivity of Snail in the nucleus of the GAC(poor differentiation);D,Negative immunoreactivity of Snail in the control group;E,Negative immunoreactivity of KAI1 in the GAC(moderate differentiation);F,Positive immunoreactivity of KAI1 in the membrane and cytoplasm of the control groups.Scale bar,100μm
2 Snail的免疫反應(yīng)性增高促進(jìn)GAC的浸潤(rùn)和轉(zhuǎn)移
對(duì)照組中Snail蛋白的免疫反應(yīng)陽(yáng)性率為5.0%,GAC組中的免疫反應(yīng)陽(yáng)性率為60.9%(圖1C,圖1D),GAC組較對(duì)照組顯著升高。且Snail蛋白的陽(yáng)性率與GAC患者的性別、年齡、腫瘤位置及腫瘤類(lèi)型等無(wú)相關(guān)性。Snail蛋白的陽(yáng)性率與GAC組織的分化程度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期高低等均相關(guān)(表1)。Snail蛋白陽(yáng)性率與GAC的腫瘤大小有關(guān)。
表1 GAC中Twist、Snail和KAI1的免疫反應(yīng)性以及與臨床病理因素之間的關(guān)系Table 1 Correlation of Twist,Snail,and KAI1 immunoreactivity and clinicopathological characteristics in GAC
3 KAI1的免疫反應(yīng)性降低促進(jìn)GAC的浸潤(rùn)和轉(zhuǎn)移
KAI1蛋白在對(duì)照組和GAC組中的免疫反應(yīng)陽(yáng)性率分別為100%和38.3%(圖1E,圖1F),GAC組較對(duì)照組顯著降低。KAI1蛋白的免疫反應(yīng)陽(yáng)性率與GAC腫瘤組織的分化程度、浸潤(rùn)深度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期均有關(guān),與GAC患者的年齡、性別、腫瘤大小、腫瘤位置及腫瘤類(lèi)型等無(wú)關(guān)(表1)。
4 GAC組織中Twist、Snail和KAI1表達(dá)之間的相互關(guān)系
Spearman等級(jí)相關(guān)分析顯示,KAI1在GAC中免疫反應(yīng)性與Twist的免疫反應(yīng)性呈負(fù)相關(guān)關(guān)系;從表2可以看出,在GAC組織中KAI1與Snail的免疫反應(yīng)性呈負(fù)相關(guān);從表2可以看出,在GAC組織中Twist與Snai的免疫反應(yīng)性l呈正相關(guān)。
5 多因素分析
將GAC組織分化程度(分為高分化組、中分化組與低分化組)、年齡(分為≥60歲組與<60歲組)、腫瘤大?。ǚ譃椋?.0cm組、4.0cm≤D<8.0cm組和≥8.0cm組)、腫瘤位置(分為胃竇組、賁門(mén)組和幽門(mén)組)、性別(分為男性組和女性組)、腫瘤類(lèi)型(分為息肉組、潰瘍組和浸潤(rùn)組、淋巴結(jié)轉(zhuǎn)移(分為轉(zhuǎn)移組與無(wú)轉(zhuǎn)移組)、臨床病理分期(分為Ⅰ+Ⅱ組和Ⅲ+Ⅳ組)、浸潤(rùn)深度(分為黏膜下組、漿膜下組、漿膜外組及累犯鄰近組織組)、Snail免疫反應(yīng)組(分為陽(yáng)性組與陰性組)、Twist免疫反應(yīng)組(分為陽(yáng)性組與陰性組)、KAI1免疫反應(yīng)組(分為陽(yáng)性組與陰性組)等因素引入COX多因素模型進(jìn)行分析,結(jié)果表明Twist和KAI1蛋白的免疫反應(yīng)陽(yáng)性和臨床病理分期是影響GAC患者生存的獨(dú)立預(yù)后因素(表3)。
6 生存分析
本組病例總的5年生存率為34.9%(91/261)。Kaplan-Meier生存分析顯示Twist蛋白免疫反應(yīng)陽(yáng)性組患者的總體生存時(shí)間明顯短于其陰性組患者,差異有統(tǒng)計(jì)學(xué)意義(圖2A);Snail蛋白免疫反應(yīng)陽(yáng)性組患者的總體生存時(shí)間明顯低于其陰性組患者(圖2B);KAI1蛋白免疫反應(yīng)陽(yáng)性患者的總體生存時(shí)間明顯高于其陰性組患者(圖2C)。
圖2 Twist、Snail或KAI1免疫反應(yīng)性與GAC患者生存曲線(xiàn)。A,Twist;B,Snail;C,KAI1Fig.2 Immunoreactivity of Twist,Snail or KAI1 and survival curves of GAC patients.A,Twist;B,Snail;C,KAI1
表2 GAC中Twist、Snail和KAI1之間的相互關(guān)系Table 2 The relationship of Twist,Snali,and KAI1 immunoreactivity in GAC
表3 261例GAC患者的多因素分析Table 3 Multivariate survival analysis of 261 patients with GAC
EMT賦予胚胎細(xì)胞潛在的運(yùn)動(dòng)能力,這對(duì)于胚胎器官的建立和上皮結(jié)構(gòu)的演化至關(guān)重要[15]。后來(lái)在腫瘤的研究中也發(fā)現(xiàn)了EMT現(xiàn)象。GAC同所有的上皮性癌一樣,在腫瘤細(xì)胞獲得運(yùn)動(dòng)和侵襲能力的同時(shí)會(huì)發(fā)生EMT[16,17],且EMT往往發(fā)生在癌細(xì)胞侵襲和轉(zhuǎn)移的早期階段。大量的研究表明轉(zhuǎn)錄因子Twist、Snail和ZEB等表達(dá)增高會(huì)誘導(dǎo)EMT。EMT過(guò)程與轉(zhuǎn)移相關(guān)已經(jīng)被普遍接受,但近年來(lái)有更多的研究發(fā)現(xiàn) EMT過(guò)程也可以促進(jìn)腫瘤的發(fā)生[15]。
Twist很長(zhǎng)一段時(shí)間以來(lái)因?yàn)榫哂锌沟蛲鲎饔枚幻枋鰹榘┗颍呛髞?lái)發(fā)現(xiàn)其在EMT過(guò)程起關(guān)鍵作用,從而促進(jìn)癌細(xì)胞的轉(zhuǎn)移[18,19],而降低Twist的表達(dá)可以抑制癌細(xì)胞的轉(zhuǎn)移能力[18]。本研究通過(guò)免疫組化ElivisionTMplus法研究261例GAC組織中Twist蛋白的免疫反應(yīng)結(jié)果,發(fā)現(xiàn)其在GAC組織中的免疫反應(yīng)陽(yáng)性率為62.1%,明顯高于其在對(duì)照組中免疫反應(yīng)陽(yáng)性率;Twsit蛋白的陽(yáng)性率與GAC腫瘤細(xì)胞的浸潤(rùn)深度、淋巴轉(zhuǎn)移與否及臨床病理分期高低等之間均呈正相關(guān)關(guān)系。進(jìn)一步的生存分析也顯示Twist蛋白免疫反應(yīng)陽(yáng)性組患者總的生存時(shí)間明顯低于其陰性組患者。上述結(jié)果說(shuō)明Twist蛋白免疫反應(yīng)的異常增高可能參與GAC的發(fā)展、浸潤(rùn)、轉(zhuǎn)移及復(fù)發(fā),其免疫反應(yīng)陽(yáng)性組預(yù)后不佳,與其他學(xué)者的研究結(jié)果相一致[5-6,20]。
Snail是EMT過(guò)程中另一個(gè)關(guān)鍵的轉(zhuǎn)錄因子,其結(jié)構(gòu)中含有一個(gè)可以介導(dǎo)轉(zhuǎn)錄的N末端和特異性結(jié)合DNA(鋅指結(jié)構(gòu))的C末端。研究表明,Snail在從果蠅到哺乳動(dòng)物的中胚層和神經(jīng)嵴的形態(tài)發(fā)生中起著關(guān)鍵作用。TGF-β可以通過(guò)Snail的激活而誘導(dǎo)EMT過(guò)程[21]。盡管癌細(xì)胞中Snail的表達(dá)增高可以促進(jìn)EMT的形成,但其相關(guān)的信號(hào)通路和下游的分子機(jī)制不清楚[16]。本研究發(fā)現(xiàn)Snail蛋白在GAC組織中的免疫反應(yīng)陽(yáng)性率(60.1%)顯著高于其在對(duì)照組中的免疫反應(yīng)陽(yáng)性率(5.0%);進(jìn)一步研究發(fā)現(xiàn)Snail蛋白的免疫反應(yīng)陽(yáng)性率與GAC腫瘤組織大小、分化程度、浸潤(rùn)深度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期等之間均呈正相關(guān)關(guān)系。即Snail蛋白免疫反應(yīng)異常增高可能參與了GAC的增殖、浸潤(rùn)及轉(zhuǎn)移過(guò)程,生存分析也顯示Snail蛋白免疫反應(yīng)陽(yáng)性組患者其生存時(shí)間短。上述結(jié)果與文獻(xiàn)報(bào)道一致[15,22]。
腫瘤轉(zhuǎn)移抑制因子KAI1屬于4次跨膜糖蛋白超家族的重要成員之一。腫瘤細(xì)胞KAI1免疫反應(yīng)缺失,因此喪失了KAI1對(duì)腫瘤細(xì)胞的運(yùn)動(dòng)、增殖及分化能力的抑制,從而導(dǎo)致腫瘤細(xì)胞的侵襲及轉(zhuǎn)移[23]。本研究發(fā)現(xiàn)KAI1蛋白在對(duì)照組中的免疫反應(yīng)陽(yáng)性率為100%,而在GAC組中的免疫反應(yīng)陽(yáng)性率為38.3%,兩組之間差異有統(tǒng)計(jì)學(xué)意義。隨后的研究發(fā)現(xiàn),KAI1蛋白的免疫反應(yīng)陽(yáng)性率與GAC腫瘤細(xì)胞浸潤(rùn)程度、分化程度、淋巴結(jié)轉(zhuǎn)移與否及臨床病理分期高低等均呈負(fù)相關(guān)關(guān)系。上述結(jié)果提示KAI1蛋白的免疫反應(yīng)卻是可能參與了GAC的發(fā)展、浸潤(rùn)及轉(zhuǎn)移過(guò)程,且KAI1免疫反應(yīng)陰性提示預(yù)后不良[11,24]。p53基因突變可以導(dǎo)致KAI1蛋白免疫反應(yīng)下調(diào)或喪失,從而使其失去了抑制腫瘤細(xì)胞轉(zhuǎn)移的能力。
本研究Spearman相關(guān)分析顯示,在GAC中Twist和Snail的免疫反應(yīng)性呈正相關(guān)關(guān)系。KAI1與Twist和Snail的免疫反應(yīng)性均呈負(fù)相關(guān)關(guān)系。Twist和Snail均是EMT過(guò)程中的關(guān)鍵轉(zhuǎn)錄因子,它們的表達(dá)異常增高參與了GAC的發(fā)生[15]。并且隨著它們的表達(dá)進(jìn)一步增高,導(dǎo)致GAC細(xì)胞的形態(tài)由原來(lái)的圓形或立方形變成運(yùn)動(dòng)能力強(qiáng)的梭形,且細(xì)胞之間的黏附力和極性降低或喪失,細(xì)胞外基質(zhì)重塑,造成上皮細(xì)胞向間充質(zhì)細(xì)胞轉(zhuǎn)化而引起GAC細(xì)胞的侵襲及轉(zhuǎn)移。KAI1蛋白的表達(dá)降低或缺失則導(dǎo)致腫瘤細(xì)胞之間的黏附力進(jìn)一步降低,最終造成腫瘤細(xì)胞更易于浸潤(rùn)及轉(zhuǎn)移。COX多因素回歸模型分析結(jié)果顯示Twist和KAI1蛋白的陽(yáng)性情況以及臨床病理分期是影響GAC患者術(shù)后生存的獨(dú)立預(yù)后因素。
綜上所述,Twist和Snail的異常增高均可能會(huì)到導(dǎo)致GAC的發(fā)生,并且可能是EMT形成的基礎(chǔ);EMT和KAI1的免疫反應(yīng)缺失直接參與了GAC細(xì)胞的浸潤(rùn)及轉(zhuǎn)移,它們均意味著患者預(yù)后不良。因此,早期聯(lián)合檢測(cè)Twist、Snail和KAI1蛋白的免疫反應(yīng)性可以作為評(píng)估GAC患者浸潤(rùn)、轉(zhuǎn)移及預(yù)后的指標(biāo)。
[1]Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin.2011,61(2):69-90.
[2]Zhao P,Li YZ and Lu YL.Aberrant expression of CD 133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.BMC cancer,2010;10:218.
[3] Polyak K,Weinberg RA.Transitions between epithelial and mesenchymal states:acquisition of malignant and stem cell traits.Nat Rev Cancer,2009,9(4):265-273.
[4]Zeisberg M,Neilson EG.Biomarkers for epithelial-mesenchymal transitions.JClinInvest,2009,119(6): 1429-1437.
[5]Yang J,Mani SA,Weinberg RA.Exploring a new twist on tumor metastasis.Cancer Res,2006,66(9):4549-4552.
[6] Kallergi G,Papadaki MA,Politaki E,et al.Epithelialmesenchymal transition markers expressed in circulating tumor cells of early and metastatic breast cancer patients. Breast Cancer Res,2011,13(3):R59.
[7]韓正全,龔曉萌.Twist和maspin在乳腺浸潤(rùn)性導(dǎo)管癌及原位癌中水平增高.中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志,2015,24(6):542-547.
[8]Gras B,Jacqueroud L,Wierinckx A,et al.Snail family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammry epithelial cells.Plos One,2014,9(3):e92254.
[9]Batlle E,Sancho E,F(xiàn)ranci C,et al.The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumor cell.Nat cell Biol,2000,2(2):84-89.
[10]Kudo-Saito C,Shirako H,Takeuchi T,et al.Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.Cancer Cell,2009,15(3):195-206.
[11]Guo C,Liu QG,Zhang L,et al.Expression and clinical significance of p53,JunB and KAI1/CD82 in human hepatocellular carcinoma.HepatobiliaryPancreatDisInt,2009,8(4):389-396.
[12]Yu L,Zhou L,Wu S,et al.Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/ CD82 expression in laryngeal squamous cell carcinoma. World J Surg Oncol,2014,12:118.
[13]齊琦,武世伍,承澤農(nóng),等.KAI1/CD82和Gli1在胃腺癌組織中的表達(dá)及其臨床意義.中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志 2014,23(3):282-286.
[14]Wu S,Yu L,Wang D,et al.Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.BMC Cancer,2012,12:535.
[15]Gras B,Jacqueroud L,Wierinckx A,et al.Snail family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammry epithelial cells.Plos One,2014,9(3):e92254.
[16]Liu CW,Li CH,Peng YJ,et al.Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer.Oncotarget,2014,5(11):3880-3894.
[17]Thierp JP,Acloque H,Huang RY,et al.Epithelial-mesenchymal transitions in development and disease.Cell,2009,139(5):871-890.
[18]Yang J,Mani SA,Donaher JL,et al.Twist,a master regulator of morphogenesis,plays an essential role in tumor metastasis.Cell,2004,117(7):927-939.
[19]郭蘇陽(yáng),李勝澤,郭偉,等。Twist和E-cadherin在宮頸鱗癌中的表達(dá)及其與KAI1表達(dá)的關(guān)系。華中科技大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2015,44(4):411-415.
[20]范瓊,鮑偉,楊婷婷,等.Twist、E-cadherin、N-cadherin在宮頸鱗癌中的表達(dá)及意義.上海交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2012,32(6):783-787.
[21]Zhu ML,Kyprianou N.Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancers cells.FASEB J,2010,24(3): 769-777.
[22]Bruyere F,Namdarian B,Corcoran NM,et al.Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers.Urol Oncol,2010,28(6): 591-596.
[23]Malik FA,Sanders AJ,Jiang WG.KAI-1/CD82,the molecule and clinical implication in cancer and cancer metastasis.Histol Histopathol,2009,24(4):519-530.
[24]周蕾,武世伍,俞嵐,等.胃腺癌中KAI1的表達(dá)及其與血管淋巴管生成的關(guān)系.四川大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2014,45(1):43-48.
Immunoreactivities of Twist,Snail and KAI1 in gastric adenocarcinoma and their clinicopathological significance
Lu Guoyu1,Wu Xiaofei1,Zhang Xiaohua1,Zhou Lei2*
(1Department of Emergency,2Department of Pathology,the First Affiliated Hospital of Bengbu Medical College,Bengbu 233003,China)
Objective To detect the immunoreactivity of the epithelial mesenchymal transition(EMT)related markers of Twist and Snail and that of the tumor metastasis suppressor KAI1 in primary gastric adenocarcinoma(GAC),and explore their association with the clinicopathological characteristics.Methods Immunoreactivity of Twist,Snail,and KAI1 protein was investigated by immunohistochemistry in 261 specimens of GAC tissues and 80 specimens of normal gastric tissues(as the control group).Results The positive rate of immunoreactivity of Twist and Snail was significantly higher in GAC tissues than in control tissues;and that of KAI1 was significantly lower in GAC than in control tissues.The positive rate of immunoreactivity of Twist and Snail was significantly related to invasion,lymph node metastasis,and pTNM stage.There was a negative association between the immunoreactivity of KAI1 protein and differentiation grade,invasion,lymph node metastasis,and pTNM stage.Kaplan-Meier survival analysis showed that the survival time of patients with positive Twist and Snail was significantly shorter than that of negative patients;and the survival time of patients with positive KAI1 was significantly longer than that of negative patients.Spearman analysis showed that there was a negative correlation between the positive immunoreactivity of KAI1 and that of Twist or Snail;and there was a positive correlation between the positive immunoreactivity of Twist and that of Snail.COX multivariate analysis showed that the positive immunoreactivity of Twist and KAI1 protein,and pTNM stage were independent prognostic factors of GAC patients.Conclusion The abnormal immunoreactivity of Twist,Snail,and KAI1 may be involved in the development,invasion,and metastasis of GAC.The combined detection of Twist,Snail,and KAI1 has an important role in predicting the progression and prognosis of GAC.
gastric neoplasm;Twist;Snail;KAI1;prognosis
R735.2
A
10.16705/j.cnki.1004-1850.
2015-08-15 〔修回日期〕2016-02-25
安徽省高等學(xué)校自然科學(xué)研究項(xiàng)目(KJ2015B099by);蚌埠醫(yī)學(xué)院自然科學(xué)研究項(xiàng)目(byky1337)
陸國(guó)玉,男(1971年),漢族,副主任醫(yī)師
(To whom correspondence should be addressed):zhou_lei03@163.com